EYPT FY 2024 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$43M-6.0% YoY

Gross Profit

$40M91.4% margin

Operating Income

-$146M-337.1% margin

Net Income

-$131M-302.4% margin

EPS (Diluted)

$-2.32

Cash Flow

Operating Cash Flow

-$126M

Free Cash Flow

-$130M

Stock-Based Comp.

$37M

Balance Sheet

Total Assets

$418M

Total Liabilities

$82M

Stockholders' Equity

$337M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$43M	$46M	-6.0%
Gross Profit	$40M	$41M	-4.4%
Operating Income	-$146M	-$75M	-94.3%
Net Income	-$131M	-$71M	-84.9%